GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (STU:ASZ1) » Definitions » Institutional Ownership

Alimera Sciences (STU:ASZ1) Institutional Ownership : 4.48% (As of May. 21, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Alimera Sciences Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Alimera Sciences's institutional ownership is 4.48%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Alimera Sciences's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Alimera Sciences's Float Percentage Of Total Shares Outstanding is 39.14%.


Alimera Sciences Institutional Ownership Historical Data

The historical data trend for Alimera Sciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alimera Sciences Institutional Ownership Chart

Alimera Sciences Historical Data

The historical data trend for Alimera Sciences can be seen below:

2023-05-31 2023-06-30 2023-07-31 2023-08-31 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-03-31 2024-04-30
Institutional Ownership 9.20 9.70 9.70 1.63 1.41 1.41 2.02 3.65 4.48 4.48

Alimera Sciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Alimera Sciences (STU:ASZ1) Business Description

Traded in Other Exchanges
Address
6310 Town Square, Suite 400, Alpharetta, GA, USA, 30005
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.

Alimera Sciences (STU:ASZ1) Headlines

No Headlines